Pharma News

Merck's Boceprevir scores high in Phase-III hepatitis C trial

Merck said that its hepatitis C drug boceprevir hit its primary endpoints in two Phase III studies and will file for an approval of the potential blockbuster by the end of this year. And analysts quickly began to handicap Merck's chances against Vertex, which has compiled a mountain of positive data for its hep C drug telaprevir.

More Damning Evidence Against GSK and FDA on Rosiglitazone

Further evidence has come to light suggesting that GlaxoSmithKline knew about an increased cardiac risk with the diabetes drug rosiglitazone (Avandia) as early as 2001 but withheld the data and that certain officials at the FDA conspired with the company to minimize the impact of later safety results. The news comes on the same day that the FDA advisory panel starts its two-day hearing on the cardiovascular safety of the drug.

Stem cell therapy can help tame cancer to manageable levels

Within ten years from now, cancer can be tamed with the application of stem cell therapy and the killer disease could be made a manageable one. For this, India should take measures to develop medical practitioners with expertise in the field of cancer biology, latest techniques like gene therapy, DNA micro array and stem cell research, said Dr V Parthasarathy, associate professor, Department of Pharmaceutical sciences, Annamalai University.

Natalizumab Improves Language Processing in Patients With Multiple Sclerosis

Treatment with natalizumab (Tysabri, Biogen Idec and Elan) leads to improved language processing and retrieval of newly learned verbal material in patients with multiple sclerosis (MS), according to research presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.

Oral Nicorandil Greatly Lowers Risk for Death in Hemodialysis Patients

In a study of hemodialysis patients without angiographic evidence of obstructive coronary artery disease, oral nicorandil lowered the risk for cardiac death by more than 85%. Coronary artery disease is one of the leading causes of death in patients on hemodialysis, and even hemodialysis patients without significant coronary lesions are at elevated risk for cardiac death.

Pages